Fair point. I don't claim I have any idea of what I am talking...

Fair point. I don't claim I have any idea of what I am talking about here but I presume fast tracked drug repurposing trials, off-label prescriptions, patents and product exclusive periods will all come into play once a drug is on the market for one indication. The more entities involve the messier it will get especially in the same region. A pharma dosen't own market exclusivity for long and the clock starts ticking once it is approved. Ophan drug designation is rewarded for the molecule not indications. I guess there are always finite additional indications that the first pharma that takes the drug to market can exclusively investigate or licence out. After that it is fair game for all without needing a licence? Realistically, if 2591 is as good as we think it is, it will take decades to realise its full poteitial probably long after the patent expires